{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:30:33Z","timestamp":1794011433727,"version":"4.8.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) shows activity in multiple myeloma (MM), yet relapse remains common owing to heterogeneous BCMA expression and soluble BCMA (sBCMA). Improving BCMA-directed CAR-T therapy requires persistence, enhanced antitumor activity, tolerance to low antigen density and resistance to sBCMA-mediated inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified anti-BCMA VHHs from a humanized phage display library, constructed monospecific and biparatopic CARs, and evaluated their function and optimal designs in preclinical models, including patient-derived MM cells and xenografts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Biparatopic Nab5822 CAR-T cells exhibited superior cytotoxicity and cytokine secretion (IL-2, IFN-\u03b3, TNF-\u03b1) against antigen-heterogeneous MM cells in vitro, maintained activity under a supraphysiological sBCMA challenge at 120\u2009ng\/mL, and retained function under repeated exposure to clinically relevant sBCMA levels. Under repeated antigen challenge, Nab5822 preserved lysis, reduced exhaustion with an increased stem-cell memory T-cell compartment, and achieved durable tumor control in xenograft models without detectable toxicity. Mechanistic analyses indicated that the VHHs engage non-overlapping BCMA epitopes and promote improved immunological synapse organization together with coordinated proximal signaling, features that are not fully explained by equilibrium affinity alone and may contribute to sustained long-term T-cell function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings support biparatopic CAR design as a strategy to tolerate low antigen density and resist sBCMA-mediated inhibition, providing a rationale for clinical evaluation of next-generation CAR T-cell therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08533-z","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:56:06Z","timestamp":1782737766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Humanized biparatopic nanobody-based CAR-T cells overcome antigen-heterogeneity in multiple myeloma"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3173-1011","authenticated-orcid":false,"given":"Jincai","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"1","key":"8533_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;5(1):25. https:\/\/doi.org\/10.1186\/s43556-024-00188-w.","journal-title":"Mol Biomed"},{"issue":"6","key":"8533_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/biom14060725","volume":"14","author":"BE Barton","year":"2024","unstructured":"Barton BE, Collins MK, Chau CH, Choo-Wosoba H, Venzon DJ, Steinebach C, et al. Preclinical evaluation of a novel series of polyfluorinated thalidomide analogs in drug-resistant multiple myeloma. Biomolecules. 2024;14(6):725. https:\/\/doi.org\/10.3390\/biom14060725.","journal-title":"Biomolecules"},{"key":"8533_CR3","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2024.286027","volume":"110","author":"O Beyar-Katz","year":"2025","unstructured":"Beyar-Katz O, Rejeski K, Shouval R. Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies. Haematologica. 2025;110:1254\u201368. https:\/\/doi.org\/10.3324\/haematol.2024.286027.","journal-title":"Haematologica"},{"issue":"1","key":"8533_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13(1):164. https:\/\/doi.org\/10.1186\/s13045-020-01001-1.","journal-title":"J Hematol Oncol"},{"key":"8533_CR5","doi-asserted-by":"publisher","first-page":"1055028","DOI":"10.3389\/fmmed.2022.1055028","volume":"2","author":"C D\u2019Accardo","year":"2022","unstructured":"D\u2019Accardo C, Porcelli G, Mangiapane LR, Modica C, Pantina VD, Roozafzay N, et al. Cancer cell targeting by CAR-T cells: a matter of stemness. Front Mol Med. 2022;2:1055028. https:\/\/doi.org\/10.3389\/fmmed.2022.1055028.","journal-title":"Front Mol Med"},{"key":"8533_CR6","doi-asserted-by":"publisher","first-page":"1476859","DOI":"10.3389\/fimmu.2024.1476859","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou J, Lei B, Shi F, Luo X, Wu K, Xu Y, et al. CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Front Immunol. 2024;15:1476859. https:\/\/doi.org\/10.3389\/fimmu.2024.1476859.","journal-title":"Front Immunol"},{"key":"8533_CR7","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153.","journal-title":"Front Immunol"},{"issue":"4","key":"8533_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41571-025-00992-5","volume":"22","author":"TJ Bock","year":"2025","unstructured":"Bock TJ, Colonne CK, Fiorenza S, Turtle CJ. Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma. Nat Rev Clin Oncol. 2025;22(4):241\u201361. https:\/\/doi.org\/10.1038\/s41571-025-00992-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"8533_CR9","doi-asserted-by":"publisher","unstructured":"van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446\u201361. https:\/\/doi.org\/10.1016\/S2352-3026(21)00057-0.","DOI":"10.1016\/S2352-3026(21)00057-0"},{"issue":"7","key":"8533_CR10","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.3390\/biomedicines11072086","volume":"11","author":"B Effer","year":"2023","unstructured":"Effer B, Perez I, Ulloa D, Mayer C, Mu\u00f1oz F, Bustos D, et al. Therapeutic targets of Monoclonal antibodies used in the treatment of cancer: current and emerging. Biomedicines. 2023;11(7):2086. https:\/\/doi.org\/10.3390\/biomedicines11072086.","journal-title":"Biomedicines"},{"key":"8533_CR11","doi-asserted-by":"publisher","unstructured":"Li D, Que Y, Ding S, Hu G, Wang W, Mao X, et al. Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report. J Immunother Cancer. 2022;10(9):e005403. https:\/\/doi.org\/10.1136\/jitc-2022-005403.","DOI":"10.1136\/jitc-2022-005403"},{"issue":"4","key":"8533_CR12","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.ymthe.2025.12.037","volume":"34","author":"KR DeGolier","year":"2026","unstructured":"DeGolier KR, Pham-Danis C, Burciaga SD, Walsh ZH, Brzezinski C, Novak AJ, et al. Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR. Mol Ther. 2026;34(4):2175\u201388. https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.037.","journal-title":"Mol Ther"},{"issue":"3","key":"8533_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ccell.2025.02.008","volume":"43","author":"C Pham-Danis","year":"2025","unstructured":"Pham-Danis C, Novak AJ, Danis E, McClellan SM, Leach L, Yarnell MC, et al. Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell. 2025;43(3):482\u2013502.e9. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.008.","journal-title":"Cancer Cell"},{"issue":"8","key":"8533_CR14","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"8533_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ajh.27225","volume":"99","author":"BA Costa","year":"2024","unstructured":"Costa BA, Ortiz RJ, Lesokhin AM, Richter J. Soluble B-cell maturation antigen in multiple myeloma. Am J Hematol. 2024;99(4):727\u201338. https:\/\/doi.org\/10.1002\/ajh.27225.","journal-title":"Am J Hematol"},{"key":"8533_CR16","doi-asserted-by":"publisher","first-page":"963689725137420","DOI":"10.1177\/09636897251374203","volume":"34","author":"M Fu","year":"2025","unstructured":"Fu M, Niu S, Liu C, Mu J, Gao S, An G, et al. Correlation between the expression of soluble BCMA and short-term\/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma. Cell Transpl. 2025;34:9636897251374203. https:\/\/doi.org\/10.1177\/09636897251374203.","journal-title":"Cell Transpl"},{"issue":"1","key":"8533_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s13402-024-00984-0","volume":"48","author":"B Sierro-Martinez","year":"2025","unstructured":"Sierro-Martinez B, Escamilla-G\u00f3mez V, P\u00e9rez-Ortega L, Guijarro-Albaladejo B, Hern\u00e1ndez-D\u00edaz P, de la Rosa-Garrido M, et al. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. Cell Oncol (Dordr). 2025;48(1):219\u201337. https:\/\/doi.org\/10.1007\/s13402-024-00984-0.","journal-title":"Cell Oncol (Dordr)"},{"issue":"11","key":"8533_CR18","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","volume":"8","author":"E Letouze","year":"2024","unstructured":"Letouze E, Moreau P, Munshi N, Samur M, Minvielle S, Touzeau C. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Adv. 2024;8(11):2952\u201359. https:\/\/doi.org\/10.1182\/bloodadvances.2023012354.","journal-title":"Blood Adv"},{"key":"8533_CR19","doi-asserted-by":"publisher","unstructured":"Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, et al. Summary of the 2019 blood and marrow Ttransplant clinical trials network myeloma intergroup workshop on minimal residual disease and immune profiling. Biol Blood Marrow Transplant. 2020;26(10):e247\u201355. https:\/\/doi.org\/10.1016\/j.bbmt.2020.06.011.","DOI":"10.1016\/j.bbmt.2020.06.011"},{"key":"8533_CR20","doi-asserted-by":"publisher","unstructured":"Katsarou A, Sj\u00f6strand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci Transl Med. 2021;13(623):eabh1962. https:\/\/doi.org\/10.1126\/scitranslmed.abh1962.","DOI":"10.1126\/scitranslmed.abh1962"},{"issue":"1","key":"8533_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","volume":"38","author":"C Li","year":"2024","unstructured":"Li C, Xu J, Luo W, Liao D, Xie W, Wei Q, et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2024;38(1):149\u201359. https:\/\/doi.org\/10.1038\/s41375-023-02065-x.","journal-title":"Leukemia"},{"issue":"1","key":"8533_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-025-01713-2","volume":"18","author":"H Yao","year":"2025","unstructured":"Yao H, Ren S-H, Wang L-H, Ren M-Q, Cai J, Chen D, et al. BCMA\/GPRC5D bispecific CAR T-cell therapy for relapsed\/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial. J Hematol Oncol. 2025;18(1):56. https:\/\/doi.org\/10.1186\/s13045-025-01713-2.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"8533_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med. 2022;28(2):345\u201352. https:\/\/doi.org\/10.1038\/s41591-021-01621-1.","journal-title":"Nat Med"},{"key":"8533_CR24","doi-asserted-by":"publisher","first-page":"1118610","DOI":"10.3389\/fimmu.2023.1118610","volume":"14","author":"G Schepisi","year":"2023","unstructured":"Schepisi G, Gianni C, Cursano MC, Gall\u00e0 V, Menna C, Casadei C, et al. Immune checkpoint inhibitors and chimeric antigen receptor (CAR)-T cell therapy: potential treatment options against testicular germ cell tumors. Front Immunol. 2023;14:1118610. https:\/\/doi.org\/10.3389\/fimmu.2023.1118610.","journal-title":"Front Immunol"},{"issue":"7","key":"8533_CR25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","volume":"24","author":"AJ Cowan","year":"2023","unstructured":"Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN, et al. \u03b3-secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24(7):811\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(23)00246-2.","journal-title":"The Lancet Oncol"},{"issue":"6","key":"8533_CR26","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","volume":"43","author":"T Rakhshandehroo","year":"2025","unstructured":"Rakhshandehroo T, Mantri SR, Moravej H, Louis BBV, Salehi Farid A, Munaretto L, et al. A CAR enhancer increases the activity and persistence of CAR T cells. Nat Biotechnol. 2025;43(6):948\u201359. https:\/\/doi.org\/10.1038\/s41587-024-02339-4.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"8533_CR27","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells9051182","volume":"9","author":"K Fujiwara","year":"2020","unstructured":"Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N. Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold. Cells. 2020;9(5):1182. https:\/\/doi.org\/10.3390\/cells9051182.","journal-title":"Cells"},{"issue":"6","key":"8533_CR28","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41375-025-02580-z","volume":"39","author":"K Marhelava","year":"2025","unstructured":"Marhelava K, Fidyt K, Pepek M, Krawczyk M, Forcados C, Malinowska A, et al. LILRB1-directed CAR-T cells for the treatment of hematological malignancies. Leukemia. 2025;39(6):1395\u2013411. https:\/\/doi.org\/10.1038\/s41375-025-02580-z.","journal-title":"Leukemia"},{"issue":"2","key":"8533_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s13577-022-00670-z","volume":"35","author":"T Huan","year":"2022","unstructured":"Huan T, Chen D, Liu G, Zhang H, Wang X, Wu Z, et al. Activation-induced cell death in CAR-T cell therapy. Hum Cell. 2022;35(2):441\u201347. https:\/\/doi.org\/10.1007\/s13577-022-00670-z.","journal-title":"Hum Cell"},{"issue":"1","key":"8533_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","volume":"43","author":"M Ando","year":"2020","unstructured":"Ando M, Ito M, Srirat T, Kondo T, Yoshimura A. Memory T cell, exhaustion, and tumor immunity. Immunol Med. 2020;43(1):1\u20139. https:\/\/doi.org\/10.1080\/25785826.2019.1698261.","journal-title":"Immunological Med"},{"issue":"2","key":"8533_CR31","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/bloodadvances.2023010607","volume":"8","author":"SY Wang","year":"2024","unstructured":"Wang SY, Scurti GM, Dalheim AV, Quinn S, Stiff PJ, Nishimura MI. Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior. Blood Adv. 2024;8(2):324\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2023010607.","journal-title":"Blood Adv"},{"issue":"1","key":"8533_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12672-024-01159-x","volume":"15","author":"Q Chen","year":"2024","unstructured":"Chen Q, Sun Y, Li H. Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment. Discov Oncol. 2024;15(1):289. https:\/\/doi.org\/10.1007\/s12672-024-01159-x.","journal-title":"Discov Oncol"},{"issue":"8010","key":"8533_CR33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang Y-K, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629(8010):201\u201310. https:\/\/doi.org\/10.1038\/s41586-024-07242-1.","journal-title":"Nature"},{"key":"8533_CR34","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.omtm.2021.10.006","volume":"23","author":"B Deng","year":"2021","unstructured":"Deng B, Pan J, Liu Z, Liu S, Chen Y, Qu X, et al. Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL. Mol Ther Methods Clin Dev. 2021;23:633\u201343. https:\/\/doi.org\/10.1016\/j.omtm.2021.10.006.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"8533_CR35","doi-asserted-by":"publisher","first-page":"104729","DOI":"10.1016\/j.critrevonc.2025.104729","volume":"211","author":"K Wang","year":"2025","unstructured":"Wang K, Ou K, Zeng Y, Yue C, Zhuo Y, Wang L, et al. Epigenetic landscapes drive CAR-T cell kinetics and fate decisions: bridging persistence and resistance. Crit Rev Oncol\/Hematol. 2025;211:104729. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104729.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5376","key":"8533_CR36","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1126\/science.281.5376.572","volume":"281","author":"EN Kersh","year":"1998","unstructured":"Kersh EN, Shaw AS, Allen PM. Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation. Science. 1998;281(5376):572\u201375. https:\/\/doi.org\/10.1126\/science.281.5376.572.","journal-title":"Science"},{"key":"8533_CR37","doi-asserted-by":"publisher","unstructured":"Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021;14(697). https:\/\/doi.org\/10.1126\/scisignal.abe2606.","DOI":"10.1126\/scisignal.abe2606"},{"issue":"3","key":"8533_CR38","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang C-H, Saso K, et al. A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352\u201359. https:\/\/doi.org\/10.1038\/nm.4478.","journal-title":"Nat Med"},{"issue":"9","key":"8533_CR39","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","volume":"29","author":"Z Dai","year":"2021","unstructured":"Dai Z, Mu W, Zhao Y, Jia X, Liu J, Wei Q, et al. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. Mol Ther. 2021;29(9):2707\u201322. https:\/\/doi.org\/10.1016\/j.ymthe.2021.07.001.","journal-title":"Mol Ther"},{"key":"8533_CR40","doi-asserted-by":"publisher","first-page":"1159507","DOI":"10.3389\/fbioe.2023.1159507","volume":"11","author":"Y Chen","year":"2023","unstructured":"Chen Y, Huang P, Niu M, Tian C, Zhang T, Peng Z. Regeneration of T cells from human-induced pluripotent stem cells for CAR-T cell medicated immunotherapy. Front Bioeng Biotechnol. 2023;11:1159507. https:\/\/doi.org\/10.3389\/fbioe.2023.1159507.","journal-title":"Front Bioeng Biotechnol"},{"key":"8533_CR41","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol. 2023;14:1101495. https:\/\/doi.org\/10.3389\/fimmu.2023.1101495.","journal-title":"Front Immunol"},{"issue":"1","key":"8533_CR42","doi-asserted-by":"publisher","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","volume":"20","author":"D Goyco Vera","year":"2024","unstructured":"Goyco Vera D, Waghela H, Nuh M, Pan J, Lulla P. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum Vaccin Immunother. 2024;20(1):2378543. https:\/\/doi.org\/10.1080\/21645515.2024.2378543.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"1","key":"8533_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan D, Madduri D, Hocking J. CAR-T cell therapy in multiple myeloma: current status and future challenges. Blood Cancer J. 2024;14(1):206. https:\/\/doi.org\/10.1038\/s41408-024-01191-8.","journal-title":"Blood Cancer J"},{"key":"8533_CR44","doi-asserted-by":"publisher","unstructured":"Ouyang W, Jin S-W, Xu N, Liu W-Y, Zhao H, Zhang L, et al. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J Immunother Cancer. 2024;12(4):e008429. https:\/\/doi.org\/10.1136\/jitc-2023-008429.","DOI":"10.1136\/jitc-2023-008429"},{"issue":"9","key":"8533_CR45","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuc\u00e1 G, et al. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2(9):904\u201318. https:\/\/doi.org\/10.1038\/s43018-021-00244-2.","journal-title":"Nat Cancer"},{"issue":"4","key":"8533_CR46","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s43018-025-00927-0","volume":"6","author":"S Simon","year":"2025","unstructured":"Simon S, Bugos G, Prins R, Rajan A, Palani A, Heyer K, et al. Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy. Nat Cancer. 2025;6(4):647\u201365. https:\/\/doi.org\/10.1038\/s43018-025-00927-0.","journal-title":"Nat Cancer"},{"issue":"1","key":"8533_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40364-025-00755-5","volume":"13","author":"S Guo","year":"2025","unstructured":"Guo S, Xi X. Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs. Biomark Res. 2025;13(1):41. https:\/\/doi.org\/10.1186\/s40364-025-00755-5.","journal-title":"Biomark Res"},{"key":"8533_CR48","doi-asserted-by":"publisher","first-page":"118819","DOI":"10.1016\/j.biopha.2025.118819","volume":"193","author":"AR Eisa","year":"2025","unstructured":"Eisa AR, Tavassoli Razavi F, Hoseinzadeh A, Haghmorad D, Baharlou R. Nanobody CAR-T cells in cancer: from molecular design to clinical translation. Biomed Pharmacother. 2025;193:118819. https:\/\/doi.org\/10.1016\/j.biopha.2025.118819.","journal-title":"Biomed Pharmacother"},{"key":"8533_CR49","doi-asserted-by":"publisher","unstructured":"Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10(2):e107\u201316. https:\/\/doi.org\/10.1016\/S2352-3026(22)00372-6.","DOI":"10.1016\/S2352-3026(22)00372-6"},{"issue":"9","key":"8533_CR50","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306. https:\/\/doi.org\/10.1038\/s41591-023-02491-5.","journal-title":"Nat Med"},{"key":"8533_CR51","doi-asserted-by":"publisher","unstructured":"Freeman R, Shahid S, Khan AG, Mathew SC, Souness S, Burns ER, et al. Developing a membrane-proximal CD33-targeting CAR T cell. J Immunother Cancer. 2024;12(5):e009013. https:\/\/doi.org\/10.1136\/jitc-2024-009013.","DOI":"10.1136\/jitc-2024-009013"},{"key":"8533_CR52","doi-asserted-by":"publisher","first-page":"119110","DOI":"10.1016\/j.biopha.2026.119110","volume":"196","author":"J Li","year":"2026","unstructured":"Li J, Li D, Huang Y, Zhou W, Li J, Wang F, et al. Membrane-proximal binding of PSMA facilitates synapse formation with CAR and enhances antitumor activity of PSMA CAR-T cells against prostate cancer. Biomed Pharmacother. 2026;196:119110. https:\/\/doi.org\/10.1016\/j.biopha.2026.119110.","journal-title":"Biomed Pharmacother"},{"key":"8533_CR53","doi-asserted-by":"publisher","first-page":"1711448","DOI":"10.3389\/fimmu.2025.1711448","volume":"16","author":"X Liu","year":"2025","unstructured":"Liu X, Guo L, Wang Y, Meng X, Shao Y, Fan X, et al. Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells. Front Immunol. 2025;16:1711448. https:\/\/doi.org\/10.3389\/fimmu.2025.1711448.","journal-title":"Front Immunol"},{"issue":"17","key":"8533_CR54","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","volume":"25","author":"S Ramakrishna","year":"2019","unstructured":"Ramakrishna S, Highfill SL, Walsh Z, Nguyen SM, Lei H, Shern JF, et al. Modulation of target antigen density improves CAR T-cell functionality and persistence. Clin Cancer Res. 2019;25(17):5329\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3784.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"8533_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2025.5628","volume":"56","author":"H Liu","year":"2025","unstructured":"Liu H, Liu X, Zhou X, Duan S, Huang X, Fei H, et al. Application of nanobody\u2011based CAR\u2011T in tumor immunotherapy (review). Int J Mol Med. 2025;56(5):1\u201319. https:\/\/doi.org\/10.3892\/ijmm.2025.5628.","journal-title":"Int J Mol Med"},{"key":"8533_CR56","doi-asserted-by":"publisher","first-page":"1411393","DOI":"10.3389\/fimmu.2024.1411393","volume":"15","author":"M Rossi","year":"2024","unstructured":"Rossi M, Breman E. Engineering strategies to safely drive CAR T-cells into the future. Front Immunol. 2024;15:1411393. https:\/\/doi.org\/10.3389\/fimmu.2024.1411393.","journal-title":"Front Immunol"},{"issue":"7","key":"8533_CR57","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00262-025-04039-7","volume":"74","author":"MA Aboalela","year":"2025","unstructured":"Aboalela MA, Abdelmoneim M, Matsumura S, Eissa IR, Bustos-Villalobos I, Sibal PA, et al. Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression. Cancer Immunol Immunother. 2025;74(7):202. https:\/\/doi.org\/10.1007\/s00262-025-04039-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"8533_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40164-025-00621-y","volume":"14","author":"MA Saliu","year":"2025","unstructured":"Saliu MA, Wang Q, Salisu MD, Ren Y, Zhang P, Suleiman RB, et al. Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer. Exp Hematol Oncol. 2025;14(1):27. https:\/\/doi.org\/10.1186\/s40164-025-00621-y.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"8533_CR59","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","volume":"15","author":"D Kegyes","year":"2022","unstructured":"Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B, et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient? J Hematol Oncol. 2022;15(1):78. https:\/\/doi.org\/10.1186\/s13045-022-01296-2.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"8533_CR60","doi-asserted-by":"publisher","first-page":"2516676","DOI":"10.1080\/19420862.2025.2516676","volume":"17","author":"MF Erasmus","year":"2025","unstructured":"Erasmus MF, Teixeira AAR, Molina E, Rodriguez Carnero LA, Li J, Knight D, et al. Developing drug-like single-domain antibodies (VHH) from in vitro libraries. Mabs-austin. 2025;17(1):2516676. https:\/\/doi.org\/10.1080\/19420862.2025.2516676.","journal-title":"Mabs-austin"},{"issue":"1","key":"8533_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13568-023-01659-z","volume":"14","author":"RJ Dorosky","year":"2024","unstructured":"Dorosky RJ, Schreier JE, Lola SL, Sava RL, Coryell MP, Akue A, et al. Nanobodies as potential tools for microbiological testing of live biotherapeutic products. AMB Express. 2024;14(1):9. https:\/\/doi.org\/10.1186\/s13568-023-01659-z.","journal-title":"AMB Express"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08533-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08533-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08533-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:37:49Z","timestamp":1789601869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08533-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8533"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08533-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human peripheral blood mononuclear cells (PBMCs) from healthy donors were purchased from Sailybio (Shanghai, China). Informed consent was obtained from all donors before specimen collection, in accordance with the principles of the Declaration of Helsinki (Approval NO. SL-WBC-202101). All animal experiments were conducted under a protocols approved by the Animal Research Committee of Shanghai YouShuLife Technology Co., Ltd (Approval No. YS-m202408002), in accordance with CNAS accreditation criteria and AAALAC International standards.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JCZ, KW, BXL, XRL, and XWH are listed as inventors on patent applications related to BCMA-specific CARs. All authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1191"}}